Blueprint Medicines disclosed new PROTAC compounds targeting CDK4, claiming proteolysis‑based degradation as a route to overcome resistance to classical kinase inhibitors. Separately, Gluetacs Therapeutics revealed molecular glue degraders built on cereblon binders reported to target a broad range of disease drivers. Both intellectual‑property filings reflect a wider industry shift toward targeted protein degradation—PROTACs and molecular glues—that aims to convert previously undruggable proteins into degradable liabilities. Patent activity accelerates as companies position for first‑in‑class clinical candidates and potential partnering opportunities.